[go: up one dir, main page]

MX2023009562A - Formas de monohidrato y cristalinas de 6-[(3s,4s)-4-metil-1-(pirim idin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a]pirazin-8-ona. - Google Patents

Formas de monohidrato y cristalinas de 6-[(3s,4s)-4-metil-1-(pirim idin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a]pirazin-8-ona.

Info

Publication number
MX2023009562A
MX2023009562A MX2023009562A MX2023009562A MX2023009562A MX 2023009562 A MX2023009562 A MX 2023009562A MX 2023009562 A MX2023009562 A MX 2023009562A MX 2023009562 A MX2023009562 A MX 2023009562A MX 2023009562 A MX2023009562 A MX 2023009562A
Authority
MX
Mexico
Prior art keywords
monohydrate
pyrazin
tetrahydropyran
pyrrolidin
pyrimidin
Prior art date
Application number
MX2023009562A
Other languages
English (en)
Inventor
Suzanne Buttar
Jun Xu
Mateusz Pitak
Adam Ross Patterson
Samuel Alexander Stratford
Ioana Sovago
Peng Zhou
Haojuan Wei
Kuangchu Dai
Original Assignee
Cardurion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals Inc filed Critical Cardurion Pharmaceuticals Inc
Publication of MX2023009562A publication Critical patent/MX2023009562A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación se refiere a una forma cristalina monohidratada del Compuesto 1 (ver Fórmula) (Compuesto 1), caracterizada porque la forma cristalina monohidratada es MH2, que tiene un patrón XRPD que comprende picos de ángulos 2? en 9.0, 11.6, 15.0, 16.0, 18.6, 19.1, 20.4, o 20.6 grados 2?, cada ±0.2 grados 2?.
MX2023009562A 2018-05-25 2020-11-24 Formas de monohidrato y cristalinas de 6-[(3s,4s)-4-metil-1-(pirim idin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a]pirazin-8-ona. MX2023009562A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676381P 2018-05-25 2018-05-25
US201962788323P 2019-01-04 2019-01-04

Publications (1)

Publication Number Publication Date
MX2023009562A true MX2023009562A (es) 2023-08-22

Family

ID=68617192

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020012636A MX2020012636A (es) 2018-05-25 2019-05-23 Formas de monohidrato y cristalinas de 6-[(3s,4s)-4-metil-1-(pirim idin-2- ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a]pirazin-8- ona.
MX2023009562A MX2023009562A (es) 2018-05-25 2020-11-24 Formas de monohidrato y cristalinas de 6-[(3s,4s)-4-metil-1-(pirim idin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a]pirazin-8-ona.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020012636A MX2020012636A (es) 2018-05-25 2019-05-23 Formas de monohidrato y cristalinas de 6-[(3s,4s)-4-metil-1-(pirim idin-2- ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a]pirazin-8- ona.

Country Status (21)

Country Link
US (2) US12006319B2 (es)
EP (2) EP4349403A3 (es)
JP (2) JP2021526134A (es)
CN (2) CN112469413B (es)
AU (1) AU2019275075B2 (es)
BR (2) BR112020024019A2 (es)
CA (1) CA3100988A1 (es)
DK (1) DK3801526T3 (es)
ES (1) ES2975792T3 (es)
FI (1) FI3801526T3 (es)
HR (1) HRP20240363T1 (es)
HU (1) HUE065709T2 (es)
IL (1) IL278875A (es)
LT (1) LT3801526T (es)
MA (1) MA52792A (es)
MX (2) MX2020012636A (es)
PL (1) PL3801526T3 (es)
PT (1) PT3801526T (es)
SI (1) SI3801526T1 (es)
WO (1) WO2019226944A1 (es)
ZA (1) ZA202401459B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4335497A3 (en) 2015-07-07 2024-05-01 H. Lundbeck A/S Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases
MX2020012636A (es) 2018-05-25 2021-01-29 Imara Inc Formas de monohidrato y cristalinas de 6-[(3s,4s)-4-metil-1-(pirim idin-2- ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a]pirazin-8- ona.
BR112021003686A2 (pt) 2018-08-31 2021-05-18 Imara Inc. inibidores de pde9 para tratar doença falciforme
TW202108585A (zh) * 2019-05-07 2021-03-01 美商伊馬拉公司 用於治療地中海型貧血之pde9抑制劑
CN116847846A (zh) * 2020-10-27 2023-10-03 卡都瑞恩医药公司 用于治疗心脏衰竭的pde9抑制剂

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB587992A (en) 1944-12-11 1947-05-12 Charles William Scaife Improvements in and relating to the production of organic nitrogen compounds
US3578687A (en) 1968-01-30 1971-05-11 Texaco Inc Process for producing 4-nitroalkanoic acids
US3819561A (en) 1970-10-23 1974-06-25 Aerojet General Co Wetting agents for non-aqueous dispersions
JPS5313608B2 (es) 1972-06-16 1978-05-11
JPS5318013B2 (es) 1973-03-19 1978-06-13
US4599430A (en) 1981-12-21 1986-07-08 The Standard Oil Company Nitrogenation of hydrocarbons, including the production of maleimide
JPS62132804A (ja) 1985-12-05 1987-06-16 Aguro Kanesho Kk 植物生長調節剤
US5412137A (en) 1993-06-07 1995-05-02 Sandoz Ltd. Process for preparing phosphinyloxy propanaminium inner salt derivatives
US5716988A (en) 1994-08-08 1998-02-10 Debiopharm S.A. Pharmaceutically stable preparation of oxaliplatinum
CA2202503C (en) 1994-10-13 2008-07-15 Antonio Ferrante Modified polyunsaturated fatty acids
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5741211A (en) 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
GB9618420D0 (en) 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
WO1999022719A1 (fr) 1997-10-30 1999-05-14 Morishita Jintan Co., Ltd. Preparation de capsule contenant un acide gras insature ou un derive de celui-ci, et procede de fabrication
IL135462A0 (en) 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
AU5565599A (en) 1998-08-14 2000-03-06 Dante J. Marciani Chemically modified saponins and the use thereof as adjuvants
WO2000043392A2 (de) 1999-01-20 2000-07-27 Arzneimittelwerk Dresden Gmbh Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel
DE60037818D1 (de) 1999-04-01 2008-03-06 Esperion Therapeutics Inc Ether-verbindungen, zusammensetzungen und ihre verwendung
AU5319499A (en) 1999-07-22 2001-02-13 Ivan L. Cameron Fatty acids to minimize cancer therapy side effects
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
AUPQ291499A0 (en) 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
US6346231B1 (en) 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
IL139457A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20010037598A1 (en) 1999-12-14 2001-11-08 Suppes Galen J. Process for producing cetane improvers from triglycerides
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
AR030416A1 (es) 2000-04-13 2003-08-20 Pharmacia Corp COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
ES2239155T3 (es) 2000-06-28 2005-09-16 Zambon Group S.P.A. Proceso para la preparacion de nitroalquenos.
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
PT1368022E (pt) 2001-03-02 2007-10-01 Debiopharm Sa Utilização de um frasco em vidro que contém uma solução de oxaliplatina
OA12506A (en) 2001-04-18 2006-05-29 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors.
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
JPWO2002102364A1 (ja) 2001-06-18 2004-09-30 山田　幸子 ＰＰＡＲγ作動性医薬組成物
CN1571672A (zh) 2001-08-17 2005-01-26 匹兹堡大学 给予雌二醇代谢物治疗或预防肥胖症、代谢综合征、糖尿病以及血管和肾脏疾病
GB0123961D0 (en) 2001-10-05 2001-11-28 Astrazeneca Ab Process and intermediates
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
PL370599A1 (en) 2001-11-02 2005-05-30 Pfizer Products Inc. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
CA2465117C (en) 2001-11-06 2012-01-03 Brigham And Women's Hospital, Inc. Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
GB2388111A (en) 2002-05-01 2003-11-05 Bayer Ag Novel imidazotriazinone compounds
US6684626B1 (en) 2002-07-30 2004-02-03 General Electric Company Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
JP2006503014A (ja) 2002-08-20 2006-01-26 プロテミックス コーポレイション リミティド 剤形及び関連する治療法
AU2003272738B2 (en) 2002-09-27 2010-04-01 Martek Biosciences Corporation Docosahexaenoic acid for improved glycemic control
AU2003284885A1 (en) 2002-10-21 2004-05-13 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2005016864A1 (en) 2003-07-29 2005-02-24 The Arizona Disease Control Research Commission Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
US20050136103A1 (en) 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
BRPI0416118A (pt) 2003-10-31 2007-01-02 Pfizer Prod Inc inibição da fosfodiesterase 9 como tratamento para estados relacionados com a obesidade
EP1718602A4 (en) 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd THERAPEUTIC AND CARRIER MOLECULES
MXPA06011871A (es) 2004-04-15 2007-10-08 Chiasma Inc Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
US7776916B2 (en) 2004-04-28 2010-08-17 The Uab Research Foundation Nitrated lipids and methods of making and using thereof
US7872095B2 (en) 2004-07-19 2011-01-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
WO2006011397A1 (ja) 2004-07-27 2006-02-02 Kowa Company., Ltd. 糖尿病の予防または治療のための薬剤
EA010802B1 (ru) 2004-11-19 2008-12-30 Мартек Байосайенсиз Корпорейшн Оксилипины из полиненасыщенных жирных кислот с длинной цепью и способы их получения и применения
EP1817009A2 (en) 2004-11-24 2007-08-15 Spi Pharma, Inc. Orally disintegrating compositions
AU2011202664B2 (en) 2004-12-08 2012-04-05 Cedars-Sinai Medical Center Methods for diagnosis and treatment of Crohn's disease
WO2006086727A2 (en) 2005-02-09 2006-08-17 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
WO2008008767A2 (en) 2006-07-14 2008-01-17 Cedars-Sinai Medical Center Methods of using ppar-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer
AU2007275658B2 (en) 2006-07-19 2011-09-01 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of mucositis
WO2008029589A1 (en) 2006-09-08 2008-03-13 Tokuyama Corporation Method and equipment for producing group-iii nitride
CA2672591A1 (en) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Treating agent of uropathy
EP2489667B1 (en) 2006-12-13 2015-04-15 ASKA Pharmaceutical Co., Ltd. Quinoxaline derivative
JP2010519311A (ja) 2007-02-20 2010-06-03 マーテック バイオサイエンシーズ コーポレーション 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法
GEP20125405B (en) 2007-05-11 2012-02-27 Pfizer Amino-heterocyclic compounds
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
WO2009038671A2 (en) 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for treating autoimmune diseases
ES2638463T3 (es) * 2008-03-10 2017-10-20 Takeda Pharmaceutical Company Limited Cristal de compuesto de bencimidazol
US20110092594A1 (en) 2008-04-18 2011-04-21 Tianxin Yang Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions
US20090326070A1 (en) 2008-05-01 2009-12-31 Complexa Inc. Vinyl substituted fatty acids
WO2009149496A1 (en) 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2010012777A1 (en) 2008-07-29 2010-02-04 Nerviano Medical Sciences S.R.L. THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
EP2350043B9 (en) 2008-10-09 2014-08-20 TEKMIRA Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
AU2009334476B2 (en) 2008-12-31 2013-08-29 Nitromega Corp. Nutraceuticals containing nitro fatty acids
US8937194B2 (en) 2008-12-31 2015-01-20 Nitromega Corp. Topical compositions containing nitro fatty acids
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
US20100286272A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
US20100286271A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Nitro-alkyl Compound Compositions
US20100286257A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
US20110082147A1 (en) 2009-07-24 2011-04-07 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
EP2459510A4 (en) 2009-07-29 2013-08-07 Phenomenome Discoveries Inc HYDROXIDE-FATTY ACID COMPOSITIONS AND USES THEREOF FOR ILLNESS TREATMENT AND DIAGNOSIS
EP2459189A4 (en) 2009-07-31 2013-01-16 Univ Pittsburgh FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
EP2483233A4 (en) 2009-10-02 2013-08-14 Complexa Inc HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
EP2499120A4 (en) 2009-11-09 2013-06-26 Medivir Ab NEW 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN HEMMER
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
WO2011113507A2 (en) 2010-03-15 2011-09-22 Ulrich Dietz Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
BR112012027915A2 (pt) 2010-05-13 2018-10-23 Nitromega Corp nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
WO2012006014A2 (en) 2010-06-28 2012-01-12 Complexa, Inc. Multi-component pharmaceuticals for treating diabetes
WO2012040230A1 (en) 2010-09-20 2012-03-29 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
CA2861795C (en) 2011-10-07 2018-12-04 Eisai R&D Management Co., Ltd. Pyrazoloquinoline derivative
IN2015DN02829A (es) * 2011-10-10 2015-09-11 Lundbeck & Co As H
US9271952B2 (en) 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
DE102012008730A1 (de) 2011-12-02 2013-06-06 Dr. Budz GmbH Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
CN107082783B (zh) 2012-01-26 2019-03-22 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
AU2013214846B2 (en) 2012-02-01 2017-09-07 City Of Hope Ribonucleotide reductase inhibitors and methods of use
US10435367B2 (en) 2013-03-14 2019-10-08 City Of Hope Indirubin derivatives, and uses thereof
US20150018417A1 (en) 2012-02-03 2015-01-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fatty acids as anti-inflammatory agents
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN
US10058688B2 (en) 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
ES2902833T3 (es) 2012-08-31 2022-03-30 Taris Biomedical Llc Sistemas y métodos de administración de fármacos para el tratamiento de cáncer de vejiga que comprenden oxaliplatino
US20140271844A1 (en) 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
EP2983730B1 (en) 2013-04-10 2019-10-16 Massachusetts Institute of Technology Local drug delivery devices and methods for treating cancer
WO2014183108A1 (en) 2013-05-10 2014-11-13 Nitromega Corp. Nutritional or dietary supplements containing fatty acids and nitrite
WO2014204872A2 (en) 2013-06-14 2014-12-24 Complexa, Inc. Composition and method for inhibition of pkng from mycobacterium tuberculosis
WO2015023557A1 (en) 2013-08-12 2015-02-19 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
WO2015073527A1 (en) 2013-11-12 2015-05-21 Complexa, Inc. Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
WO2015185499A1 (en) 2014-06-06 2015-12-10 H. Lundbeck A/S Pde9 inhibitors with 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbonitrile backbone
US20180092948A1 (en) 2015-04-02 2018-04-05 Aobiome Llc Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria
EP4335497A3 (en) 2015-07-07 2024-05-01 H. Lundbeck A/S Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases
US10537541B2 (en) 2015-10-02 2020-01-21 Complexa Inc. Treatment of focal segmental glomerular sclerosis (FSGS) using therapeutically effective oral doses of 10-nitro-9(E)-octadec-9-enoic acid
CA3014395A1 (en) 2016-02-19 2017-08-24 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors
CA3025586A1 (en) 2016-07-06 2018-01-11 Imara, Inc. Pde9 inhibitors for treatment of peripheral diseases
MX2019014049A (es) 2017-05-26 2020-07-28 Imara Inc Metodos de fabricacion y uso de inhibidores de pde9.
MX2020012636A (es) 2018-05-25 2021-01-29 Imara Inc Formas de monohidrato y cristalinas de 6-[(3s,4s)-4-metil-1-(pirim idin-2- ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a]pirazin-8- ona.
BR112021003686A2 (pt) 2018-08-31 2021-05-18 Imara Inc. inibidores de pde9 para tratar doença falciforme
JP2022527630A (ja) 2019-04-05 2022-06-02 イマラ インク． 鎌状赤血球症を治療するためのｐｄｅ９阻害剤
TW202108585A (zh) 2019-05-07 2021-03-01 美商伊馬拉公司 用於治療地中海型貧血之pde9抑制劑

Also Published As

Publication number Publication date
CN117843645A (zh) 2024-04-09
MX2020012636A (es) 2021-01-29
EP3801526A1 (en) 2021-04-14
KR20210014662A (ko) 2021-02-09
EP3801526B1 (en) 2023-12-27
EP3801526A4 (en) 2022-04-06
IL278875A (en) 2021-01-31
HRP20240363T1 (hr) 2024-06-07
US20210107911A1 (en) 2021-04-15
SI3801526T1 (sl) 2024-05-31
PT3801526T (pt) 2024-03-26
PL3801526T3 (pl) 2024-08-05
MA52792A (fr) 2021-04-14
US12006319B2 (en) 2024-06-11
ES2975792T3 (es) 2024-07-15
HUE065709T2 (hu) 2024-06-28
BR112020024019A2 (pt) 2021-02-23
LT3801526T (lt) 2024-04-10
EP4349403A3 (en) 2024-06-05
DK3801526T3 (da) 2024-03-25
US12466832B2 (en) 2025-11-11
CA3100988A1 (en) 2019-11-28
CN112469413A (zh) 2021-03-09
WO2019226944A1 (en) 2019-11-28
FI3801526T3 (fi) 2024-03-20
CN112469413B (zh) 2024-01-12
BR122023022641A2 (pt) 2024-02-20
ZA202401459B (en) 2025-07-30
US20240199627A1 (en) 2024-06-20
JP2021526134A (ja) 2021-09-30
EP4349403A2 (en) 2024-04-10
JP2024095561A (ja) 2024-07-10
AU2019275075A1 (en) 2021-01-14
AU2019275075B2 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
MX2023009562A (es) Formas de monohidrato y cristalinas de 6-[(3s,4s)-4-metil-1-(pirim idin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a]pirazin-8-ona.
PH12015502284A1 (en) Protein kinase inhibitors
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX2018002520A (es) Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo.
CO2017004784A2 (es) Isómeros de ácido-1-[(3-cloro-2-fluoro-fenil)metil]-4-[[3-fluoro-6-[(5-metil-1h-pirazol-3-il)amino]-2-piridil]metil]-2-metil-piperidin-4-carboxílico como inhibidores de la cinasa aurora a
UY40179A (es) Sal hemi-tolueno de (3s,5s,6r,8s)-8-alil-6-(3-clorofenil)-5-(4- clorofenil)-3-isopropil-8-metil-2,3,5,6,7,8-hexahidrooxazolo [3,2-a]piridin-4-io naftaleno-1-sulfonato, y su preparación
MX393499B (es) Derivados de pirazolopirimidina como inhibidor de cinasa
BR112014003693A2 (pt) amino quinazolinas como inibidores de quinase
CR20110620A (es) Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus
MY191628A (en) Novel triazolo[4,5-d]pyrimidine derivatives
NZ722624A (en) Fused pyrimidines as inhibitors of p97 complex
EA201890820A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
WO2015017607A3 (en) METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS
MX2015016513A (es) Bisulfato del inhibidor de la janus quinasa (jak) y metodo de preparacion para el mismo.
JO3318B1 (ar) مثبطات bace
MX387236B (es) Compuestos de pirimidina que contienen grupos ácidos
GEP201706673B (en) Compositions containing chondroitin sulphate, proteolytic enzymes and sulphydryl compounds for improving the bioavailability of chondroitin sulphate
USD754863S1 (en) Nail correction tool
WO2015114638A3 (en) Use of casein kinase i inhibitors for depleting stem cells
WO2014160177A3 (en) Quinazoline inhibitors of pi3k
WO2020055544A3 (en) Method for treating pancreatic cancer
WO2016201306A3 (en) Inhibitors of nucleotidyl transferases and use in herpes and hepatitis viral infections therefor
WO2016004280A3 (en) Inhibitors of bruton's tyrosine kinase
WO2015051268A3 (en) Hiv protease inhibitors against picornavirus infection